Tuesday, January 29, 2013
Copies of the peptide drug are fused with heat-sensitive polymers. The heat sensitivity means that the fusion protein turns to jelly once inside the body and is gradually broken down by enzymes to release the drug over time.The treatment functions in a similar way to microsphere-release technology, which sees polymer microspheres loaded up with peptide drugs and then injected under the skin.
The jelly is painless, less expensive, and easier to inject. It is said that the jelly-based system could also decrease the number of injections a patient gets while making the medication last longer. Longer lasting medication would raise patient compliance, minimize doctors visits, and make the overall treatment a better experience for the patient. This drug could especially benefit patients because of the long lasting effects, so how does a drug that is used less more profitable?
When you’re designing the formulation for the delivery system, how can predict how it will behave? At the 17th Annual Drug Delivery Partnerships, Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM, leads our session - Fixed Dose Combinations: Use Predictive Studies to Establish Potential for Success or Failure.
The event is just weeks away! Register today using code XP1878BLOG and get 15% the standard rate.
at 2:59 PM Posted by Kate